Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen-Reference-Cited by-同舟云学术

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

Published:2016-01-14 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Soulières Denis,Aguilar Jose Luis,Chen Eric,Misiukiewicz Krzysztof,Ernst Scott,Lee Hyun Jung,Bryant Katherine,He Shuang,Obasaju Coleman K.,Chang Shao-Chun,Chin Steve,Adkins Douglas

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2064-0.pdf

Reference11 articles.

1. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21 Suppl 7:vii252–61.

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancer. Version 2.2014. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf . Accessed 24 Nov 2014.

3. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.

4. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–54.

5. Erbitux Prescribing Information. Revised August 2013. Branchburg, NJ: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company. http://packageinserts.bms.com/pi/pi_erbitux.pdf . Accessed 11 Nov 2014.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shooting at Moving and Hidden Targets—Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas;Cancers;2021-12-10

2. Extrapolation: Experience gained from original biologics;Drug Discovery Today;2021-08

3. Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial;Oral Oncology;2021-04

4. Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars;BioDrugs;2020-01-10

5. Prognostic value of 18F-FDG PET/CT functional parameters in patients with head and neck cancer;Nuclear Medicine Communications;2019-04